Asset Details
Do you wish to reserve the book?
Efficacy and Safety of Chin Augmentation Using MaiLi-E, a Lidocaine-Containing Cross-Linked Sodium Hyaluronate Gel
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and Safety of Chin Augmentation Using MaiLi-E, a Lidocaine-Containing Cross-Linked Sodium Hyaluronate Gel
Do you wish to request the book?
Efficacy and Safety of Chin Augmentation Using MaiLi-E, a Lidocaine-Containing Cross-Linked Sodium Hyaluronate Gel
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and Safety of Chin Augmentation Using MaiLi-E, a Lidocaine-Containing Cross-Linked Sodium Hyaluronate Gel
2025
Overview
Background
MaiLi-E is a lidocaine-containing cross-linked sodium hyaluronate gel for dermal filling. This prospective, multicenter, randomized, delayed-treatment controlled, evaluator-blinded clinical trial aims to evaluate the efficacy and safety of MaiLi-E for chin augmentation.
Methods
Participants with mild-to-moderate–severe chin retrusion were enrolled and randomized (2:1) to receive MaiLi-E at study onset (MaiLi-E group) or six months later (control group). The primary efficacy endpoint was the response rate of chin retrusion improvement, defined as the percentage of participants whose China (Allergan) Chin Retrusion Scale score improved by ≥1 point from baseline, assessed by independent investigators at Month 6 post-injection for the MaiLi-E group and Month 6 post-randomization for the control group. Safety assessments included adverse events (AEs) and treatment-related AEs.
Results
Between September 2022 and January 2023, 159 participants were enrolled (MaiLi-E group,
n
= 106; control group,
n
= 53). Response rates of chin retrusion improvement were 64.2% (95% CI 55.0–73.3%) in the MaiLi-E group and 20.8% (95% CI 9.8–31.7%) in the control group (
P
< 0.0001). Improvement rates of the Global Aesthetic Improvement Scale evaluated by participants were 91.5% (95% CI 86.2–96.8%) in the MaiLi-E group and 0.0% (95% CI 0.0–0.0%) in the control group. Response was maintained in most participants at Month 12 post-treatment. Participant satisfaction rates were 72.6% in the MaiLi-E and 74.5% in the control group. 64.8% of participants experienced AEs, and 5.0% experienced treatment-related AEs from the initial treatment to Month 6 after the last injection.
Conclusion
MaiLi-E is effective and safe in correcting mild-to-moderate–severe chin retrusion. Evidence obtained from at least one properly designed randomized controlled trial.
Level of Evidence I
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors
www.springer.com/00266
.
Publisher
Springer US,Springer Nature B.V
Subject
/ Consent
/ Dermal Fillers - administration & dosage
/ Dermal Fillers - adverse effects
/ Female
/ Gels
/ Humans
/ Hyaluronic Acid - administration & dosage
/ Hyaluronic Acid - adverse effects
/ Lidocaine - administration & dosage
/ Male
/ Medicine
/ Original
